REMDACTA trial of Actemra plus remdesivir failed to meet its primary endpoint of improved time to hospital discharge for patients with severe COVID-19 pneumonia (nor its key secondary endpoints) compared to remdesivir alone https://t.co/OyqpnwUVXU